You can now read 5 articles in a month for free on BostonGlobe.com. Read as much as you want anywhere and anytime for just 99¢.

around the region

Lexington biotech raises $84m in IPO

Concert Pharmaceuticals Inc. shares rose 18 cents to $14.18, for a modest gain of 1.3 percent in their opening day of trading on the Nasdaq exchange Thursday after the Lexington biotechnology company raised $84 million in an initial public offering.

The IPO was the fifth by a Massachusetts biotech this year. Concert joined Flexion Therapeutics Inc. of Burlington, Cambridge-based Eleven Biotherapeutics Inc., and Genocea Biosciences Inc. and Dicerna Pharmaceuticals Inc., both of Watertown, in joining the ranks of newly public companies. Nine biotechs from Massachusetts went public in 2013.

Continue reading below

Eight-year-old Concert is developing drugs to treat central nervous system disorders, renal disease, inflammation, and cancer.

In its IPO, the company sold 6 million shares at a price of $14 each, giving underwriters an option to buy an additional 900,000 shares.

A company spokeswoman said Concert executives wouldn’t discuss their plans.

Robert Weisman can be reached at robert.weisman@globe.com. Follow him on Twitter @GlobeRobW.
Loading comments...
Subscriber Log In

We hope you've enjoyed your 5 free articles'

Stay informed with unlimited access to Boston’s trusted news source.

  • High-quality journalism from the region’s largest newsroom
  • Convenient access across all of your devices
  • Today’s Headlines daily newsletter
  • Subscriber-only access to exclusive offers, events, contests, eBooks, and more
  • Less than 25¢ a week
Marketing image of BostonGlobe.com
Marketing image of BostonGlobe.com
Already a subscriber?
Your city. Your stories. Your Globe.
Yours FREE for two weeks.
Enjoy free unlimited access to Globe.com for the next two weeks.
Limited time only - No credit card required!
BostonGlobe.com complimentary digital access has been provided to you, without a subscription, for free starting today and ending in 14 days. After the free trial period, your free BostonGlobe.com digital access will stop immediately unless you sign up for BostonGlobe.com digital subscription. Current print and digital subscribers are not eligible for the free trial.
Thanks & Welcome to Globe.com
You now have unlimited access for the next two weeks.
BostonGlobe.com complimentary digital access has been provided to you, without a subscription, for free starting today and ending in 14 days. After the free trial period, your free BostonGlobe.com digital access will stop immediately unless you sign up for BostonGlobe.com digital subscription. Current print and digital subscribers are not eligible for the free trial.